Search filters
Filters
Clear All

Phase

  • 182
  • 151
  • 2
  • 188
  • 147
  • 17
  • 373
  • 1196
  • 568
  • 28
  • 44
  • 2
  • 1128
  • 1197
  • 5

Found 1202 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

HVTN 142: A Phase 1 Randomized Double-Blind Placebo-Controlled Clinical Study to Evaluate the Safety Reactogenicity and Immunogenicity of the HCMV-HIV Vaccine Candidate VIR-1388 in Adult Participants with Overall Good Health and Without HIV

99 years or below
All genders
The purpose of this study is to measure the safety, reactogenicity, and immunogenicity of VIR 1388 in adults in good health without HIV.
Learn More

RA Treatment and Common Infections Study

99 years or below
All genders
: This study is a longitudinal, observational, cohort study, recruiting patients from an existing online patient registry (ArthritisPower) and administering monthly online surveys to measure medication exposures and rates of non-hospitalized infection. This study aims to assess the risk of non-hospitalized infection associated with different immunosuppressive treatments, especially glucocorticoids, and …
Learn More

NONINTERVENTIONAL EXTENSION STUDY FOR PATIENTS TREATED IN STUDY R5459-RT-1944 WITH REGN5459 OR REGN5458 (BCMA CD3 BISPECIFIC ANTIBODIES) WHO RECEIVE A KIDNEY TRANSPLANT

99 years or below
All genders
The primary objective of the study is to assess adverse events (AEs) and serious adverse events (SAEs) in kidney transplant recipients previously treated with REGN5459 or REGN5458 in the R5459-RT-1944 study. The primary endpoint for this study is the incidence of AEs and SAEs over a 12-month period, starting at …
Learn More

UPCC 33922: An Open-Label Multicenter Study of LOXO-435 (LY3866288) In Advanced Solid Tumor Malignancies With FGFR3 Alterations

99 years or below
All genders
Phase 1
Please refer to Protocol LOXO-FG3-22001, Section 1.1.1 (Objectives and Endpoints) Please refer to Protocol LOXO-FG3-22001, Section 1.1.1 (Objectives and Endpoints) Please refer to Protocol LOXO-FG3-22001, Section 1.1.1 (Objectives and Endpoints)
Learn More

UPCC 32422 A Phase 1-2 Open-Label Study of the Safety Pharmacokinetics Pharmacodynamics and Preliminary Activity of Tolinapant in Combination with Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects with Relapsed/Refractory Peripheral T-cell Lymphoma

99 years or below
All genders
The primary purpose of the study is to assess safety, and to identify the recommended phase 2 dose (RP2D) of tolinapant in combination with oral decitabine/cedazuridine in Phase 1 and to assess preliminary efficacy as determined by overall response rate (ORR) in Phase 2.
Learn More

An Open-label Long-term Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants With Major Depressive Disorder (MDD)

99 years or below
All genders
This is an OL, multicenter, long-term study to evaluate the safety and efficacy of aticaprant 10 mg in combination with an oral antidepressant in adult and elderly participants with MDD and who have had an inadequate response to an SSRI or SNRI in the current depressive episode. Participants will enter …
Learn More

Detection and Characterization of Subclinical Atherosclerotic Plaques in High-Risk Populations of Lupus Erythematosus and Dermatomyositis Patients: A Prospective Single-Center Cohort Study

99 years or below
All genders
To determine the burden of subclinical coronary and iliofemoral arterial plaque in 30- to 50-year-old patients with lupus erythematosus (LE) or dermatomyositis (DM) but no clinically evident atherosclerotic cardiovascular disease (ASCVD); and to determine the nature, location, and characteristics of subclinical plaques in these patients. To detect the extent and …
Learn More

UPCC 35922: Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

99 years or below
All genders
Phase 1
Please see Protocol NUV-868-01, Section 3 (Objectives and Endpoints) Please see Protocol NUV-868-01, Section 3 (Objectives and Endpoints) Please see Protocol NUV-868-01, Section 3 (Objectives and Endpoints)
Learn More

UPCC 52422: A Phase 1 Multicenter Open-Label Dose-Escalation and Expansion Study to Evaluate the Safety Tolerability Pharmacokinetics Pharmacodynamics and Clinical Activity of Intravenously Administered KT-333 in Adult Patients with Relapsed or Refractory Lymphomas Large Granular Lymphocytic Leukemia and Solid Tumors

99 years or below
All genders
Phase 1
Please refer to Protocol Section 2 (Objectives and Endpoints) Please refer to Protocol Section 2 (Objectives and Endpoints) Please refer to Protocol Section 2 (Objectives and Endpoints)
Learn More

A PHASE 2 MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY SAFETY AND PHARMACOKINETICS OF REC-4881 IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS (FAP)

99 years or below
All genders
This is a multicenter, randomized, double-blind, placebo-controlled two-part trial in patients with FAP who have previously undergone a colectomy/proctocolectomy using the invesitgational product REC-4881.
Learn More
581 - 590 of 1202